These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50 related articles for article (PubMed ID: 16530275)
1. The membranes' role in the HIV-1 neutralizing monoclonal antibody 2F5 mode of action needs re-evaluation. Veiga AS; Castanho MA Antiviral Res; 2006 Aug; 71(1):69-72. PubMed ID: 16530275 [TBL] [Abstract][Full Text] [Related]
2. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems. Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693 [TBL] [Abstract][Full Text] [Related]
3. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. Julien JP; Bryson S; Nieva JL; Pai EF J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005 [TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6. Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506 [TBL] [Abstract][Full Text] [Related]
5. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies. Huarte N; Lorizate M; Kunert R; Nieva JL FEBS Lett; 2008 Nov; 582(27):3798-804. PubMed ID: 18930052 [TBL] [Abstract][Full Text] [Related]
6. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. Sánchez-Martínez S; Lorizate M; Hermann K; Kunert R; Basañez G; Nieva JL FEBS Lett; 2006 Apr; 580(9):2395-99. PubMed ID: 16616522 [TBL] [Abstract][Full Text] [Related]
8. Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: implication for mode of action. Lev N; Fridmann-Sirkis Y; Blank L; Bitler A; Epand RF; Epand RM; Shai Y Biochemistry; 2009 Apr; 48(14):3166-75. PubMed ID: 19206186 [TBL] [Abstract][Full Text] [Related]
9. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513 [TBL] [Abstract][Full Text] [Related]
10. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340 [TBL] [Abstract][Full Text] [Related]
11. Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation. Dong XN; Chen YH Immunol Lett; 2006 Aug; 106(2):180-6. PubMed ID: 16859756 [TBL] [Abstract][Full Text] [Related]
13. The influence of cholesterol on the interaction of HIV gp41 membrane proximal region-derived peptides with lipid bilayers. Veiga AS; Castanho MA FEBS J; 2007 Oct; 274(19):5096-104. PubMed ID: 17803684 [TBL] [Abstract][Full Text] [Related]
14. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5. de la Arada I; Julien JP; de la Torre BG; Huarte N; Andreu D; Pai EF; Arrondo JL; Nieva JL J Phys Chem B; 2009 Oct; 113(41):13626-37. PubMed ID: 19754136 [TBL] [Abstract][Full Text] [Related]
15. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Chomont N; Hocini H; Gody JC; Bouhlal H; Becquart P; Krief-Bouillet C; Kazatchkine M; Bélec L Virology; 2008 Jan; 370(2):246-54. PubMed ID: 17920650 [TBL] [Abstract][Full Text] [Related]
16. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope. Li J; Chen X; Jiang S; Chen YH Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5. Kusov YY; Zamjatina NA; Poleschuk VF; Michailov MI; Morace G; Eberle J; Gauss-Müller V Antiviral Res; 2007 Feb; 73(2):101-11. PubMed ID: 17014915 [TBL] [Abstract][Full Text] [Related]
18. Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex. Lorizate M; Gómara MJ; de la Torre BG; Andreu D; Nieva JL J Mol Biol; 2006 Jun; 360(1):45-55. PubMed ID: 16813835 [TBL] [Abstract][Full Text] [Related]
19. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. Scherer EM; Zwick MB; Teyton L; Burton DR AIDS; 2007 Oct; 21(16):2131-9. PubMed ID: 18090039 [TBL] [Abstract][Full Text] [Related]
20. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. Massanella M; Puigdomènech I; Cabrera C; Fernandez-Figueras MT; Aucher A; Gaibelet G; Hudrisier D; García E; Bofill M; Clotet B; Blanco J AIDS; 2009 Jan; 23(2):183-8. PubMed ID: 19098487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]